Search

Your search keyword '"Vieito, Maria"' showing total 61 results
Start Over Author "Vieito, Maria" Publisher american association for cancer research (aacr)
61 results on '"Vieito, Maria"'

1. Supplementary Figure 1 from Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors

Author

Vieito, Maria, primary, Moreno, Victor, primary, Spreafico, Anna, primary, Brana, Irene, primary, Wang, Judy S., primary, Preis, Meir, primary, Hernández, Tatiana, primary, Genta, Sofia, primary, Hansen, Aaron R., primary, Doger, Bernard, primary, Galvao, Vladimir, primary, Lenox, Laurie, primary, Brown, Regina J., primary, Kalota, Anna, primary, Mehta, Jaydeep, primary, Pastore, Friederike, primary, Patel, Bharvin, primary, Mistry, Pankaj, primary, Gu, Junchen, primary, Lauring, Josh, primary, and Patel, Manish R., primary

Published
2023
Full Text
View/download PDF

2. Supplementary Tables 1-3 from Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors

Author

Vieito, Maria, primary, Moreno, Victor, primary, Spreafico, Anna, primary, Brana, Irene, primary, Wang, Judy S., primary, Preis, Meir, primary, Hernández, Tatiana, primary, Genta, Sofia, primary, Hansen, Aaron R., primary, Doger, Bernard, primary, Galvao, Vladimir, primary, Lenox, Laurie, primary, Brown, Regina J., primary, Kalota, Anna, primary, Mehta, Jaydeep, primary, Pastore, Friederike, primary, Patel, Bharvin, primary, Mistry, Pankaj, primary, Gu, Junchen, primary, Lauring, Josh, primary, and Patel, Manish R., primary

Published
2023
Full Text
View/download PDF

3. Supplementary Tables 1-3 from Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors

Author

Vieito, Maria, primary, Moreno, Victor, primary, Spreafico, Anna, primary, Brana, Irene, primary, Wang, Judy S., primary, Preis, Meir, primary, Hernández, Tatiana, primary, Genta, Sofia, primary, Hansen, Aaron R., primary, Doger, Bernard, primary, Galvao, Vladimir, primary, Lenox, Laurie, primary, Brown, Regina J., primary, Kalota, Anna, primary, Mehta, Jaydeep, primary, Pastore, Friederike, primary, Patel, Bharvin, primary, Mistry, Pankaj, primary, Gu, Junchen, primary, Lauring, Josh, primary, and Patel, Manish R., primary

Published
2023
Full Text
View/download PDF

4. Supplementary Figure 1 from Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors

Author

Vieito, Maria, primary, Moreno, Victor, primary, Spreafico, Anna, primary, Brana, Irene, primary, Wang, Judy S., primary, Preis, Meir, primary, Hernández, Tatiana, primary, Genta, Sofia, primary, Hansen, Aaron R., primary, Doger, Bernard, primary, Galvao, Vladimir, primary, Lenox, Laurie, primary, Brown, Regina J., primary, Kalota, Anna, primary, Mehta, Jaydeep, primary, Pastore, Friederike, primary, Patel, Bharvin, primary, Mistry, Pankaj, primary, Gu, Junchen, primary, Lauring, Josh, primary, and Patel, Manish R., primary

Published
2023
Full Text
View/download PDF

5. Data from Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors

Author

Vieito, Maria, primary, Moreno, Victor, primary, Spreafico, Anna, primary, Brana, Irene, primary, Wang, Judy S., primary, Preis, Meir, primary, Hernández, Tatiana, primary, Genta, Sofia, primary, Hansen, Aaron R., primary, Doger, Bernard, primary, Galvao, Vladimir, primary, Lenox, Laurie, primary, Brown, Regina J., primary, Kalota, Anna, primary, Mehta, Jaydeep, primary, Pastore, Friederike, primary, Patel, Bharvin, primary, Mistry, Pankaj, primary, Gu, Junchen, primary, Lauring, Josh, primary, and Patel, Manish R., primary

Published
2023
Full Text
View/download PDF

6. Data from Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors

Author

Vieito, Maria, primary, Moreno, Victor, primary, Spreafico, Anna, primary, Brana, Irene, primary, Wang, Judy S., primary, Preis, Meir, primary, Hernández, Tatiana, primary, Genta, Sofia, primary, Hansen, Aaron R., primary, Doger, Bernard, primary, Galvao, Vladimir, primary, Lenox, Laurie, primary, Brown, Regina J., primary, Kalota, Anna, primary, Mehta, Jaydeep, primary, Pastore, Friederike, primary, Patel, Bharvin, primary, Mistry, Pankaj, primary, Gu, Junchen, primary, Lauring, Josh, primary, and Patel, Manish R., primary

Published
2023
Full Text
View/download PDF

7. Supplemental Table S1 from Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens

Author

Tabernero, Josep, primary, Bedard, Philippe L., primary, Bang, Yung-Jue, primary, Vieito, Maria, primary, Ryu, Min-Hee, primary, Fagniez, Nathalie, primary, Chadjaa, Mustapha, primary, Soufflet, Christine, primary, Masson, Nina, primary, and Gazzah, Anas, primary

Published
2023
Full Text
View/download PDF

9. Supplemental Table S3 from Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens

Author

Tabernero, Josep, primary, Bedard, Philippe L., primary, Bang, Yung-Jue, primary, Vieito, Maria, primary, Ryu, Min-Hee, primary, Fagniez, Nathalie, primary, Chadjaa, Mustapha, primary, Soufflet, Christine, primary, Masson, Nina, primary, and Gazzah, Anas, primary

Published
2023
Full Text
View/download PDF

11. Supplemental Figure S2 from Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens

Author

Tabernero, Josep, primary, Bedard, Philippe L., primary, Bang, Yung-Jue, primary, Vieito, Maria, primary, Ryu, Min-Hee, primary, Fagniez, Nathalie, primary, Chadjaa, Mustapha, primary, Soufflet, Christine, primary, Masson, Nina, primary, and Gazzah, Anas, primary

Published
2023
Full Text
View/download PDF

12. Supplemental Figure S2 from Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens

Author

Tabernero, Josep, primary, Bedard, Philippe L., primary, Bang, Yung-Jue, primary, Vieito, Maria, primary, Ryu, Min-Hee, primary, Fagniez, Nathalie, primary, Chadjaa, Mustapha, primary, Soufflet, Christine, primary, Masson, Nina, primary, and Gazzah, Anas, primary

Published
2023
Full Text
View/download PDF

16. Supplemental Table S4 from Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens

Author

Tabernero, Josep, primary, Bedard, Philippe L., primary, Bang, Yung-Jue, primary, Vieito, Maria, primary, Ryu, Min-Hee, primary, Fagniez, Nathalie, primary, Chadjaa, Mustapha, primary, Soufflet, Christine, primary, Masson, Nina, primary, and Gazzah, Anas, primary

Published
2023
Full Text
View/download PDF

17. Supplemental Table S1 from Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens

Author

Tabernero, Josep, primary, Bedard, Philippe L., primary, Bang, Yung-Jue, primary, Vieito, Maria, primary, Ryu, Min-Hee, primary, Fagniez, Nathalie, primary, Chadjaa, Mustapha, primary, Soufflet, Christine, primary, Masson, Nina, primary, and Gazzah, Anas, primary

Published
2023
Full Text
View/download PDF

18. Supplemental Table S5 from Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens

Author

Tabernero, Josep, primary, Bedard, Philippe L., primary, Bang, Yung-Jue, primary, Vieito, Maria, primary, Ryu, Min-Hee, primary, Fagniez, Nathalie, primary, Chadjaa, Mustapha, primary, Soufflet, Christine, primary, Masson, Nina, primary, and Gazzah, Anas, primary

Published
2023
Full Text
View/download PDF

20. Supplemental Table S3 from Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens

Author

Tabernero, Josep, primary, Bedard, Philippe L., primary, Bang, Yung-Jue, primary, Vieito, Maria, primary, Ryu, Min-Hee, primary, Fagniez, Nathalie, primary, Chadjaa, Mustapha, primary, Soufflet, Christine, primary, Masson, Nina, primary, and Gazzah, Anas, primary

Published
2023
Full Text
View/download PDF

21. Supplemental Figure S1 from Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens

Author

Tabernero, Josep, primary, Bedard, Philippe L., primary, Bang, Yung-Jue, primary, Vieito, Maria, primary, Ryu, Min-Hee, primary, Fagniez, Nathalie, primary, Chadjaa, Mustapha, primary, Soufflet, Christine, primary, Masson, Nina, primary, and Gazzah, Anas, primary

Published
2023
Full Text
View/download PDF

22. Supplemental Table S4 from Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens

Author

Tabernero, Josep, primary, Bedard, Philippe L., primary, Bang, Yung-Jue, primary, Vieito, Maria, primary, Ryu, Min-Hee, primary, Fagniez, Nathalie, primary, Chadjaa, Mustapha, primary, Soufflet, Christine, primary, Masson, Nina, primary, and Gazzah, Anas, primary

Published
2023
Full Text
View/download PDF

24. Supplemental Table S5 from Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens

Author

Tabernero, Josep, primary, Bedard, Philippe L., primary, Bang, Yung-Jue, primary, Vieito, Maria, primary, Ryu, Min-Hee, primary, Fagniez, Nathalie, primary, Chadjaa, Mustapha, primary, Soufflet, Christine, primary, Masson, Nina, primary, and Gazzah, Anas, primary

Published
2023
Full Text
View/download PDF

26. Supplemental Table S2 from Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens

Author

Tabernero, Josep, primary, Bedard, Philippe L., primary, Bang, Yung-Jue, primary, Vieito, Maria, primary, Ryu, Min-Hee, primary, Fagniez, Nathalie, primary, Chadjaa, Mustapha, primary, Soufflet, Christine, primary, Masson, Nina, primary, and Gazzah, Anas, primary

Published
2023
Full Text
View/download PDF

27. Supplemental Figure S1 from Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens

Author

Tabernero, Josep, primary, Bedard, Philippe L., primary, Bang, Yung-Jue, primary, Vieito, Maria, primary, Ryu, Min-Hee, primary, Fagniez, Nathalie, primary, Chadjaa, Mustapha, primary, Soufflet, Christine, primary, Masson, Nina, primary, and Gazzah, Anas, primary

Published
2023
Full Text
View/download PDF

28. Supplemental Table S2 from Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens

Author

Tabernero, Josep, primary, Bedard, Philippe L., primary, Bang, Yung-Jue, primary, Vieito, Maria, primary, Ryu, Min-Hee, primary, Fagniez, Nathalie, primary, Chadjaa, Mustapha, primary, Soufflet, Christine, primary, Masson, Nina, primary, and Gazzah, Anas, primary

Published
2023
Full Text
View/download PDF

30. Supplemental Table S3 from Tusamitamab ravtansine in patients with advanced solid tumors: Phase 1 study of safety, pharmacokinetics, and antitumor activity using alternative dosing regimens

Author

Tabernero, Josep, primary, Bedard, Philippe L., primary, Bang, Yung-Jue, primary, Vieito, Maria, primary, Ryu, Min-Hee, primary, Fagniez, Nathalie, primary, Chadjaa, Mustapha, primary, Soufflet, Christine, primary, Masson, Nina, primary, and Gazzah, Anas, primary

Published
2023
Full Text
View/download PDF

31. Supplemental Table S4 from Tusamitamab ravtansine in patients with advanced solid tumors: Phase 1 study of safety, pharmacokinetics, and antitumor activity using alternative dosing regimens

Author

Tabernero, Josep, primary, Bedard, Philippe L., primary, Bang, Yung-Jue, primary, Vieito, Maria, primary, Ryu, Min-Hee, primary, Fagniez, Nathalie, primary, Chadjaa, Mustapha, primary, Soufflet, Christine, primary, Masson, Nina, primary, and Gazzah, Anas, primary

Published
2023
Full Text
View/download PDF

32. Supplemental Table S1 from Tusamitamab ravtansine in patients with advanced solid tumors: Phase 1 study of safety, pharmacokinetics, and antitumor activity using alternative dosing regimens

Author

Tabernero, Josep, primary, Bedard, Philippe L., primary, Bang, Yung-Jue, primary, Vieito, Maria, primary, Ryu, Min-Hee, primary, Fagniez, Nathalie, primary, Chadjaa, Mustapha, primary, Soufflet, Christine, primary, Masson, Nina, primary, and Gazzah, Anas, primary

Published
2023
Full Text
View/download PDF

33. Tusamitamab ravtansine in patients with advanced solid tumors: Phase 1 study of safety, pharmacokinetics, and antitumor activity using alternative dosing regimens

Author

Tabernero, Josep, primary, Bedard, Philippe L., additional, Bang, Yung-Jue, additional, Vieito, Maria, additional, Ryu, Min-Hee, additional, Fagniez, Nathalie, additional, Chadjaa, Mustapha, additional, Soufflet, Christine, additional, Masson, Nina, additional, and Gazzah, Anas, additional

Published
2023
Full Text
View/download PDF

34. Supplemental Table S3 from Tusamitamab ravtansine in patients with advanced solid tumors: Phase 1 study of safety, pharmacokinetics, and antitumor activity using alternative dosing regimens

Author

Tabernero, Josep, primary, Bedard, Philippe L., primary, Bang, Yung-Jue, primary, Vieito, Maria, primary, Ryu, Min-Hee, primary, Fagniez, Nathalie, primary, Chadjaa, Mustapha, primary, Soufflet, Christine, primary, Masson, Nina, primary, and Gazzah, Anas, primary

Published
2023
Full Text
View/download PDF

35. Supplemental Table S1 from Tusamitamab ravtansine in patients with advanced solid tumors: Phase 1 study of safety, pharmacokinetics, and antitumor activity using alternative dosing regimens

Author

Tabernero, Josep, primary, Bedard, Philippe L., primary, Bang, Yung-Jue, primary, Vieito, Maria, primary, Ryu, Min-Hee, primary, Fagniez, Nathalie, primary, Chadjaa, Mustapha, primary, Soufflet, Christine, primary, Masson, Nina, primary, and Gazzah, Anas, primary

Published
2023
Full Text
View/download PDF

36. Supplemental Figure S1 from Tusamitamab ravtansine in patients with advanced solid tumors: Phase 1 study of safety, pharmacokinetics, and antitumor activity using alternative dosing regimens

Author

Tabernero, Josep, primary, Bedard, Philippe L., primary, Bang, Yung-Jue, primary, Vieito, Maria, primary, Ryu, Min-Hee, primary, Fagniez, Nathalie, primary, Chadjaa, Mustapha, primary, Soufflet, Christine, primary, Masson, Nina, primary, and Gazzah, Anas, primary

Published
2023
Full Text
View/download PDF

38. Supplemental Table S5 from Tusamitamab ravtansine in patients with advanced solid tumors: Phase 1 study of safety, pharmacokinetics, and antitumor activity using alternative dosing regimens

Author

Tabernero, Josep, primary, Bedard, Philippe L., primary, Bang, Yung-Jue, primary, Vieito, Maria, primary, Ryu, Min-Hee, primary, Fagniez, Nathalie, primary, Chadjaa, Mustapha, primary, Soufflet, Christine, primary, Masson, Nina, primary, and Gazzah, Anas, primary

Published
2023
Full Text
View/download PDF

40. Supplemental Table S2 from Tusamitamab ravtansine in patients with advanced solid tumors: Phase 1 study of safety, pharmacokinetics, and antitumor activity using alternative dosing regimens

Author

Tabernero, Josep, primary, Bedard, Philippe L., primary, Bang, Yung-Jue, primary, Vieito, Maria, primary, Ryu, Min-Hee, primary, Fagniez, Nathalie, primary, Chadjaa, Mustapha, primary, Soufflet, Christine, primary, Masson, Nina, primary, and Gazzah, Anas, primary

Published
2023
Full Text
View/download PDF

41. Supplemental Table S4 from Tusamitamab ravtansine in patients with advanced solid tumors: Phase 1 study of safety, pharmacokinetics, and antitumor activity using alternative dosing regimens

Author

Tabernero, Josep, primary, Bedard, Philippe L., primary, Bang, Yung-Jue, primary, Vieito, Maria, primary, Ryu, Min-Hee, primary, Fagniez, Nathalie, primary, Chadjaa, Mustapha, primary, Soufflet, Christine, primary, Masson, Nina, primary, and Gazzah, Anas, primary

Published
2023
Full Text
View/download PDF

42. Supplemental Table S2 from Tusamitamab ravtansine in patients with advanced solid tumors: Phase 1 study of safety, pharmacokinetics, and antitumor activity using alternative dosing regimens

Author

Tabernero, Josep, primary, Bedard, Philippe L., primary, Bang, Yung-Jue, primary, Vieito, Maria, primary, Ryu, Min-Hee, primary, Fagniez, Nathalie, primary, Chadjaa, Mustapha, primary, Soufflet, Christine, primary, Masson, Nina, primary, and Gazzah, Anas, primary

Published
2023
Full Text
View/download PDF

43. Supplemental Figure S2 from Tusamitamab ravtansine in patients with advanced solid tumors: Phase 1 study of safety, pharmacokinetics, and antitumor activity using alternative dosing regimens

Author

Tabernero, Josep, primary, Bedard, Philippe L., primary, Bang, Yung-Jue, primary, Vieito, Maria, primary, Ryu, Min-Hee, primary, Fagniez, Nathalie, primary, Chadjaa, Mustapha, primary, Soufflet, Christine, primary, Masson, Nina, primary, and Gazzah, Anas, primary

Published
2023
Full Text
View/download PDF

44. Supplemental Table S5 from Tusamitamab ravtansine in patients with advanced solid tumors: Phase 1 study of safety, pharmacokinetics, and antitumor activity using alternative dosing regimens

Author

Tabernero, Josep, primary, Bedard, Philippe L., primary, Bang, Yung-Jue, primary, Vieito, Maria, primary, Ryu, Min-Hee, primary, Fagniez, Nathalie, primary, Chadjaa, Mustapha, primary, Soufflet, Christine, primary, Masson, Nina, primary, and Gazzah, Anas, primary

Published
2023
Full Text
View/download PDF

45. Supplemental Figure S2 from Tusamitamab ravtansine in patients with advanced solid tumors: Phase 1 study of safety, pharmacokinetics, and antitumor activity using alternative dosing regimens

Author

Tabernero, Josep, primary, Bedard, Philippe L., primary, Bang, Yung-Jue, primary, Vieito, Maria, primary, Ryu, Min-Hee, primary, Fagniez, Nathalie, primary, Chadjaa, Mustapha, primary, Soufflet, Christine, primary, Masson, Nina, primary, and Gazzah, Anas, primary

Published
2023
Full Text
View/download PDF

46. Supplemental Figure S1 from Tusamitamab ravtansine in patients with advanced solid tumors: Phase 1 study of safety, pharmacokinetics, and antitumor activity using alternative dosing regimens

Author

Tabernero, Josep, primary, Bedard, Philippe L., primary, Bang, Yung-Jue, primary, Vieito, Maria, primary, Ryu, Min-Hee, primary, Fagniez, Nathalie, primary, Chadjaa, Mustapha, primary, Soufflet, Christine, primary, Masson, Nina, primary, and Gazzah, Anas, primary

Published
2023
Full Text
View/download PDF

47. Supplementary Figure 1 from Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors

Author

Vieito, Maria, primary, Moreno, Victor, primary, Spreafico, Anna, primary, Brana, Irene, primary, Wang, Judy S., primary, Preis, Meir, primary, Hernández, Tatiana, primary, Genta, Sofia, primary, Hansen, Aaron R., primary, Doger, Bernard, primary, Galvao, Vladimir, primary, Lenox, Laurie, primary, Brown, Regina J., primary, Kalota, Anna, primary, Mehta, Jaydeep, primary, Pastore, Friederike, primary, Patel, Bharvin, primary, Mistry, Pankaj, primary, Gu, Junchen, primary, Lauring, Josh, primary, and Patel, Manish R., primary

Published
2023
Full Text
View/download PDF

48. Data from Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors

Author

Vieito, Maria, primary, Moreno, Victor, primary, Spreafico, Anna, primary, Brana, Irene, primary, Wang, Judy S., primary, Preis, Meir, primary, Hernández, Tatiana, primary, Genta, Sofia, primary, Hansen, Aaron R., primary, Doger, Bernard, primary, Galvao, Vladimir, primary, Lenox, Laurie, primary, Brown, Regina J., primary, Kalota, Anna, primary, Mehta, Jaydeep, primary, Pastore, Friederike, primary, Patel, Bharvin, primary, Mistry, Pankaj, primary, Gu, Junchen, primary, Lauring, Josh, primary, and Patel, Manish R., primary

Published
2023
Full Text
View/download PDF

49. Supplementary Tables 1-3 from Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors

Author

Vieito, Maria, primary, Moreno, Victor, primary, Spreafico, Anna, primary, Brana, Irene, primary, Wang, Judy S., primary, Preis, Meir, primary, Hernández, Tatiana, primary, Genta, Sofia, primary, Hansen, Aaron R., primary, Doger, Bernard, primary, Galvao, Vladimir, primary, Lenox, Laurie, primary, Brown, Regina J., primary, Kalota, Anna, primary, Mehta, Jaydeep, primary, Pastore, Friederike, primary, Patel, Bharvin, primary, Mistry, Pankaj, primary, Gu, Junchen, primary, Lauring, Josh, primary, and Patel, Manish R., primary

Published
2023
Full Text
View/download PDF

50. Supplementary Tables 1-3 from Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors

Author

Vieito, Maria, primary, Moreno, Victor, primary, Spreafico, Anna, primary, Brana, Irene, primary, Wang, Judy S., primary, Preis, Meir, primary, Hernández, Tatiana, primary, Genta, Sofia, primary, Hansen, Aaron R., primary, Doger, Bernard, primary, Galvao, Vladimir, primary, Lenox, Laurie, primary, Brown, Regina J., primary, Kalota, Anna, primary, Mehta, Jaydeep, primary, Pastore, Friederike, primary, Patel, Bharvin, primary, Mistry, Pankaj, primary, Gu, Junchen, primary, Lauring, Josh, primary, and Patel, Manish R., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results